Dompe farmaceutici S.p.A.

Dompé farmaceutici S.p.A. is an international biopharmaceutical company headquartered in Milan, Italy, with 130+ years of history. The company operates across the full pharmaceutical value chain—research, development, manufacturing, and commercialization—specializing in primary care drugs and biotechnology targeting unmet medical needs. Key therapeutic focus areas include ophthalmic diseases (particularly rare degenerative conditions), neurological disorders, pain management, anti-inflammatory treatments, and oncology. Dompé is recognized for developing the first recombinant human Nerve Growth Factor (rhNGF) treatment, a breakthrough for rare eye diseases. The company maintains a robust R&D infrastructure with facilities in L'Aquila and collaborations with major partners including Amgen and Biogen. With ~819 employees and 2024 revenues around €268.5 million, Dompé combines family heritage with modern biotech innovation, leveraging proprietary platforms like Exscalate (AI-powered virtual drug screening) and advanced clinical trial capabilities to accelerate therapeutic discovery and market introduction across multiple indication areas.